Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D014777 | Virus Diseases NIH | 0.11 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.07 |
D018352 | Coronavirus Infections NIH | 0.06 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications similar to those produced by the SARS coronavirus in the 2002-2003 epidemic. This new disease was named COVID-19 and the causative virus SARS-CoV-2. The SARS-CoV-2 virus, enters the airway and binds, by means of the S protein on its surface to the membrane protein ACE2 in type 2 alveolar cells. The S protein-ACE2 complex is internalized by endocytosis leading to a partial decrease or total loss of the enzymatic function ACE2 in the alveolar cells and in turn increasing the tissue concentration of pro-inflammatory angiotensin II by decreasing its degradation and reducing the concentration of its physiological antagonist angiotensin 1-7. High levels of angiotensin II on the lung interstitium can promote apoptosis initiating an inflammatory process with release of proinflammatory cytokines, establishing a self-powered cascade, leading eventually to ARDS. It has recently been proposed the tentative use of agents such as losartan and telmisartan as alternative options for treating COVID-19 patients prior to development of ARDS. The present study is an open-label randomized phase II clinical trial for the evaluation of telmisartan in COVID-19 patients. Briefly, patients with confirmed diagnosis of SARS-CoV-2, will be randomized to receive 80 mg/12h of telmisartan plus standard care or standard care alone and will be monitored for development of acute respiratory distress syndrome. Other variables regarding lung function, systemic inflammation and cardiovascular function will also be evaluated.
Description: Blood oxygen saturation below 93 %
Measure: Need for supplementary oxygen Time: Within 15 days after enrollmentDescription: Correlation between arterial oxygen pressure and inspired oxygen fraction if O2 needed
Measure: PAFI02 measure Time: Daily during the first 15 days after enrollmentDescription: Number of opacified quadrants on lung Rx
Measure: Number of opacified quadrants on lung Rx Time: Every 5 days during the first 15 days after enrollmentDescription: Serum C rective protein levels
Measure: C reactive protein Time: Every three days during the first 15 days after enrollmentDescription: Lactate deshidrogenase serum levels
Measure: LDH Time: Every three days during the first 15 days after enrollmentDescription: Troponin serum levels
Measure: Troponin Time: Every three days during the first 15 days after enrollment